Search

Your search keyword '"Thomas, Leyhe"' showing total 14 results
Start Over Author "Thomas, Leyhe" Journal alzheimer's & dementia
14 results on '"Thomas, Leyhe"'

1. P3‐489: GERMAN NORMATIVE DATA FOR THE MONTREAL COGNITIVE ASSESSMENT

Author

Michael M. Ehrensperger, Nicolai Goettel, Thomas Leyhe, Manfred Berres, Andreas U. Monsch, and Alessandra E. Thomann

Subjects
Epidemiology, Health Policy, Applied psychology, Montreal Cognitive Assessment, language.human_language, German, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, language, Normative, Neurology (clinical), Geriatrics and Gerontology, Psychology
Published
2018

2. [P4–208]: CLASSIFICATION AND OVERLAP OF DEPRESSION AND DEMENTIA

Author

Thomas Leyhe

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, medicine.disease, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, medicine, Dementia, Neurology (clinical), Geriatrics and Gerontology, business, Psychiatry, Depression (differential diagnoses)
Published
2017

3. P3‐246: Influence of the Retrieval Frequency on the Memory Performance in Elderly Healthy Subjects and Patients with Alzheimer's Disease

Author

Cornelia Veil, Marko Wilke, Klaus Scheffler, Thomas Leyhe, Stephan Mueller, Christian Mychajliw, Ralf Saur, and Michael Erb

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Healthy subjects, Disease, Audiology, Memory performance, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2016

4. P4‐110: RELATIONSHIP BETWEEN HIPPOCAMPAL VOLUME AND FREQUENCY OF EVENT RETRIEVAL USING THE HISTORIC EVENTS MEMORY TEST IN PEOPLE WITH ALZHEIMER'S DISEASE

Author

Michael Erb, Ralf Saur, Klaus Scheffler, Andreas J. Fallgatter, Christian Mychajliw, Stephan Mueller, Marko Wilke, Cornelia Veil, and Thomas Leyhe

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Event retrieval, Hippocampal volume, Neurology (clinical), Disease, Geriatrics and Gerontology, Memory test, Psychology, Neuroscience
Published
2014

5. P1–327: Memory performance of past public events depends on retrieval frequency but not remoteness in Alzheimer's disease

Author

Stephan Mueller, Ralf Saur, Cornelia Veil, Franziska Hösl, Marko Wilke, Michael Erb, Christian Mychajliw, Thomas Leyhe, and Klaus Scheffler

Subjects
Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Epidemiology, Health Policy, Neurology (clinical), Disease, Geriatrics and Gerontology, Memory performance, Psychology, Cognitive psychology, Developmental psychology
Published
2013

6. P1‐028: Disequilibrium of APOE levels between serum and cerebrospinal fluid in Alzheimer's patients

Author

Christoph Laske, Thomas Leyhe, Brigitte Schreitmüller, Elke Stransky, and Walter Maetzler

Subjects
Apolipoprotein E, Pathology, medicine.medical_specialty, Glial fibrillary acidic protein, biology, Epidemiology, business.industry, Health Policy, Early disease, Neurodegeneration, Disease, medicine.disease, Pathophysiology, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Cerebrospinal fluid, Developmental Neuroscience, medicine, biology.protein, Biomarker (medicine), Neurology (clinical), Geriatrics and Gerontology, business
Abstract

especially in early disease stages. In late stages of AD Abeta and tauprotein levels have become static and are therefore unsuitable to reflect ongoing dynamic processes of AD-related neurodegeneration, such as glia cell-related pathobiology. But, it is well established that amyloid plaques are associated with activated astrocytes. Thus, astrocyte-derived proteins like glial fibrillary acidic protein (GFAP) and S100B that are detectable in CSF might serve as markers of pathophysiological events especially in advanced AD. Methods: For a sample of 68 human CSF aliquots commercially available ELISA were used for the quantitative analysis of GFAP (IBL-International, Hamburg, Germany) and S100B (IBL). We included AD patients, healthy and disease controls. First we correlated standard biomarkers (abeta and tau-protein) and glia-derived proteins, furthermore we compared biomarker levels of controls and AD patients at different disease stages. Results: When calculating the correlation coefficient (Spearman) we found a significant correlation of t-tau and GFAP (r 1⁄4 0.261, P

Published
2012

7. P3‐152: Cognitive decline as a quadratic function of free tri‐iodothyronine levels in Alzheimer's disease

Author

Ralf Saur, Jeanette Frank, Andreas J. Fallgatter, Thomas Leyhe, and Karsten Müssig

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease, Quadratic function, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Endocrinology, Developmental Neuroscience, Tri iodothyronine, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, Cognitive decline, business
Published
2012

8. P4‐226: Glial cell line‐derived neurotrophic factor in lithium‐treated patients with early Alzheimer's disease

Author

Peter Annas, Christoph Laske, Guido Straten, Ralf Saur, Hans Basun, Thomas Leyhe, and Thomas Gasser

Subjects
Oncology, medicine.medical_specialty, biology, Lithium (medication), Epidemiology, business.industry, Health Policy, Disease, Ciliary neurotrophic factor, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Neurotrophic factors, Internal medicine, biology.protein, medicine, Vitamin D and neurology, Glial cell line-derived neurotrophic factor, Neurology (clinical), Geriatrics and Gerontology, Early phase, business, GDNF family of ligands, medicine.drug
Abstract

study accounting for the treatment effect size observed in the GAP study. Conclusions: Early Phase 1 and 2 studies have demonstrated that human immunoglobulin may have potential in the treatment of mild to moderate AD. However, these preliminary findings in small groups of subjects will need to be confirmed in large-scale, multi-center Phase 3 studies. One study with Gammagard Liquid/Kiovig is currently ongoing and a second is planned to begin in 2011.

Published
2011

9. P2‐067: Significant elevation of plasma BACE in AD and MCI patients

Author

Xin Cheng, Hikmet Nural, Jason Zhong, Ping He, Yong Shen, Marwan N. Sabbagh, Kaj Blennow, Rena Li, Anders Wallin, Thomas Leyhe, Harald Hampel, and Michael Ewers

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Significant elevation, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Endocrinology, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2011

10. P1‐095: Stem cell factor plasma levels predict cognitive decline in Alzheimer's disease patients

Author

Elke Stransky, Christoph Laske, Thomas Leyhe, and Andreas J. Fallgatter

Subjects
Oncology, medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Stem cell factor, Disease, Plasma levels, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, Cognitive decline, business
Published
2011

11. P1‐456: Inverse association between amyloid‐beta 1–42 and SDF‐1 plasma levels in healthy older adults

Author

Thomas Leyhe, Meinrad Gawaz, Konstantinos Stellos, Niklas Koehler, Christoph Laske, Elke Stransky, and Gerhard W. Eschweiler

Subjects
medicine.medical_specialty, Inverse Association, biology, Epidemiology, Amyloid beta, business.industry, Health Policy, Plasma levels, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Endocrinology, Developmental Neuroscience, Internal medicine, biology.protein, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2008

12. P4‐369: Lithium trial in Alzheimer's disease: A randomized, single‐blinded, placebo‐controlled, parallel group multicentre 10‐week study

Author

Thomas Leyhe, Hans Basun, Anette Mörtberg, Katharina Bürger, Peter Schönknecht, Matthias W. Riepe, Inga Kraft, Anna Bogstedt, Johannes Schröder, Peter Annas, Alexander Kurz, Michael Ewers, Harald Hampel, Lutz Frölich, and Thomas Gasser

Subjects
medicine.medical_specialty, Lithium (medication), Epidemiology, business.industry, Health Policy, Disease, Placebo, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Developmental Neuroscience, Group (periodic table), Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, business, medicine.drug
Published
2008

13. P3–280: Higher peripheral regulatory T cell activity in parkinson but not Alzheimer's disease

Author

Daniela Berg, Daniela Rosenkranz, Thomas Gasser, Thomas Leyhe, Mathias Jucker, Sascha W. Weyer, Lars Stoltze, Alexandra Gaenslen, Hansjoerg Buehring, and Eva Tolosa

Subjects
Epidemiology, Regulatory T cell, business.industry, Health Policy, Disease, Peripheral, Psychiatry and Mental health, Cellular and Molecular Neuroscience, medicine.anatomical_structure, Developmental Neuroscience, Immunology, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2006

14. P3–340: Decrease of BDNF serum concentration from MCI to early Alzheimer's disease

Author

Klaus Schott, Elke Stransky, Niklas Koehler, Thomas Leyhe, and Christoph Laske

Subjects
medicine.medical_specialty, Epidemiology, business.industry, Health Policy, Disease, Serum concentration, Psychiatry and Mental health, Cellular and Molecular Neuroscience, Endocrinology, Developmental Neuroscience, Internal medicine, medicine, Neurology (clinical), Geriatrics and Gerontology, business
Published
2006

Catalog

Books, media, physical & digital resources
See catalog results